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ABSTRACT
Human peroxiredoxin II (Prx II) has been known to
function as an antioxidant enzyme in cells. Using head-and-
neck cancer cell lines, we investigated whether Prx II ex-
pression is related to the resistance of cells to radiation
therapy in vivo and in vitro, and whether a Prx II antisense
serves as a radiosensitizer. Increased expression of Prx II
was observed in tissues isolated from the patients who did
not respond to radiation therapy, whereas Prx II expression
was weak in tissues from the patients with regressed tumors.
Enhanced expression of Prx II in UMSCC-11A (11A) cells
was also observed after treatment with g radiation. This
increased expression conferred radiation resistance to can-
cer cells because overexpression of Prx II protected 11A cells
from radiation-induced cell death, suggesting that blocking
Prx II expression could enhance radiation sensitivity. Treat-
ment of 11A cells with a Prx II antisense decreased induction
of Prx II, enhancing the radiation sensitivity. From these
results, we suggest that stress-induced overexpression of Prx
II increases radiation resistance via protection of cancer
cells from radiation-induced oxidative cytolysis and that a
Prx II antisense can be used as a radiosensitizer.
INTRODUCTION
Radiation therapy and chemotherapy in conjunction with
surgical operations have been commonly used for the treatment
of head and neck tumors. However, a significant number of
tumors fail respond to radiation therapy and/or chemotherapy
because many forms of tumors appear to become less sensitive
or resistant to radiation and anticancer drugs after consecutive
treatments. Although extensive studies on the molecular mech-
anisms of resistance to chemo- and/or radiation therapy have
been carried out, problems related to overcoming this resistance
remain to be solved.
The mammalian Prx5 family is divided into two groups,
based on the amino acid sequences: one group in which two
cysteines are conserved (Prx I, II, III, and IV); and one group in
which one cysteine is conserved (Prx V and VI; Refs. 1–3).
Member of the Prx family have previously been known as
thioredoxin peroxidase, which reduces H2O2 using the electrons
provided by thioredoxin (4, 5). However, it is not yet established
whether all members of the Prx family found in a variety of
species actually function as a peroxidase (4–6). Some members
of the Prx family do not require thioredoxin as an electron
donor; therefore, they are not termed thioredoxin peroxidase (7).
Mammalian tissues express Prx isoforms, and their overexpres-
sion prevented intracellular accumulation of H2O2, inhibiting
apoptosis (7, 8).
Prx II has also been known as NKEF-B (9, 10). NKEF, Mr
48,000, is composed of two subunits linked by disulfide bonds
(9). It was initially found in human RBCs and was known to
play a role in enhancing cytotoxicity of natural killer cells. It
was classified into two subgroups, NKEF-A and NKEF-B,
which were later identified as Prx I and II, respectively; the
primary sequences of Prx I and II are highly homologous to each
other (10). The cDNA sequence of Prx I is homologous to a
human proliferation-associated gene (PAG), and it is known to
be associated with cell proliferation and differentiation (11). In
contrast, the cDNA sequence of Prx II shows a homology to
thiol-specific antioxidant proteins, which scavenge or suppress
formation of protein thiol radicals (2). Therefore, it has been
proposed that Prx II functions as an antioxidant protein that
protects cells from ROS or cellular oxidative damage (3, 12).
Kim et al. (13) observed that induction of Prx II mRNA
was increased in human endothelial (ECV304) cells treated with
H2O2. Moreover, overexpression of Prx II in ECV304 cells
exposed to t-butylperoxide or methyl mercury reduced ROS
generation, resulting in an increased protection from oxidative
stress (14). However, overexpression of Prx II did not protect
the cells from oxidative damages by depletion of the intracel-
lular GSH (13). It was therefore proposed that the activity of Prx
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II was regulated by protein thiol-thiol exchange via the thiore-
doxin system, but not by GSH (15).
Delays in G2 induced by basic fibroblast growth factor in
HeLa cells have been proposed to be related to radiation resist-
ance (16), and in Burkitt’s lymphoma cells, ceramide signaling
has been implicated in the radiation-resistance mechanism (17).
Although the mechanisms of chemo- and/or radiation resistance
in cancer cells is not well understood, we propose that inhibition
of the stress-activated gene induction could be promising in
efforts to overcome chemo- and/or radiation resistance. In the
present study, therefore, we examined a possible role of Prx II
in cellular resistance to radiation treatments and investigated a
Prx II antisense as a possible radiation sensitizer in head-and-
neck cancer cells.
MATERIALS AND METHODS
Cell Culture. Head and neck cancer cells (UMSCC-
11A) were generously provided by R. Lotan (University of
Texas M.D. Anderson Cancer Center, Houston, TX). 11A cells
were cultured in DMEM/F12 (Life Technologies, Grand Island,
NY) medium containing 10% fetal bovine serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin (Life Technologies).
Tissue Preparations and Northern Blot Analysis. Tu-
mor tissues were obtained from nine patients with head and neck
cancer undergoing surgical resections, rinsed with ice-cold sa-
line solution, quickly frozen in liquid nitrogen, and stored at
270°C until needed for RNA isolation. The frozen tissues were
minced with liquid nitrogen, and RNA was isolated using the
phenol-chloroform method with TRIzol reagent (Life Technol-
ogies) according to the manufacturer’s instructions. Ten mg of
total RNA per lane were fractionated on a 1% agarose-formal-
dehyde gel and transferred to a nylon membrane (NEN, Boston,
MA). The blot was probed with a 400-bp 32P-labeled ClaI-XbaI
fragment of human Prx II. Hybridization was carried out as
described previously (18).
Immunoblotting. After treatment, cells were harvested
and solubilized with RIPA buffer [150 mM NaCl, 1.0% NP40,
0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris (pH 8.0)] con-
taining protease inhibitors (1 mM sodium orthovanadate, 30 mM
NaF, 1 mM phenylmethylsulfonyl fluoride, and 30 mM sodium
pyrophosphate). Protein concentrations were determined by the
Bio-Rad protein assay (Bio-Rad, Hercules, CA). After separated
on SDS-polyacrylamide gel, the proteins were transferred to
nitrocellulose membranes, and the Prx II protein was detected
using the anti-Prx II polyclonal antibody (7).
Construction of Sense and Antisense Prx II Expression
Vector and Stable Cell Lines. A NdeI-BamHI fragment from
pETprxII (7) containing the entire coding region for Prx II was
subcloned into pcDNA3 (Invitrogen, the Netherlands) to gener-
ate pPrxII/S and pPrxII/AS. pPrxII/AS contained an inverted
NdeI-BamHI fragment of the Prx II gene. Prx II-overexpressing
cell lines were constructed in 11A cells as described previously
(19). Three colonies were isolated and cultured for the use of
clonogenic assay and Western blotting.
Clonogenic Assay. Exponentially growing cells were
counted, diluted, and seeded in triplicate at 300 cells per culture
dish (100-mm dish). Cells were incubated for 24 h in a humid-
ified CO2 incubator at 37°C, irradiated to g-rays with a 137Cs
g-ray source (Atomic Energy of Canada, Ltd., Ontario, Canada)
at a dose rate of 3.81 Gy/min. Colonies were allowed to grow
for 14 days and stained with 1% methylene blue in methanol.
Fig. 1 Prx II expression in combined chemotherapy/radiation- or
radiation therapy-resistant head-and-neck tumor tissues. Expression of
Prx II in tumor tissues from the patients with head and neck cancers was
detected using Northern blot procedure as described in “Materials and
Methods” (A). Total RNA (10 mg each) was hybridized to a radiolabeled
human Prx II cDNA probe. Equal loading was demonstrated with
ethidium bromide staining (B). The profiles of the patients are listed in
Table 1. Lane N, normal tissue from case 1; Lanes 2–5, radiotherapy-
sensitive tumors; Lanes 6–9, radiotherapy-resistant tumors.
Fig. 2 Induction of the Prx II protein after irradiation. 11A cells were
irradiated with 3 Gy, harvested at the indicated time points, and time
course expression of Prx II was detected by Western blotting with a Prx
II polyclonal antibody. Equal loading of the protein was confirmed by
Ponceau S staining.
Table 1 Profile of patients receiving chemo- or radiation therapy
Patients with head and neck tumors were divided to two groups
based on their chemo- and/or radiation therapy and tumor curability.
The efficiency of cancer therapy was determined by the condition of
remaining cancer tissues after treatments.
Case
Age
(years) Site
No. of
chemotherapy
Radiation
(cGy) Response
1 77 Larynx NDa 7020 CR
2 70 Hypopharynx 3 7020 CR
3 51 Larynx ND 6600 CR
4 64 Maxilla 1 7000 PR
5 61 Hypopharynx 3 7000 CR
6 25 Middle ear 3 7000 NR
7 55 Nasal cavity 1 5440 NR
8 63 Retromolar trigone 3 5800 NR
9 51 Parotid 3 7020 NR
a ND, not done; CR, complete response; PR, partial response; NR,
no response.
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Colonies larger than 200 mm in diameter were counted with a
colony counter (Imaging Products, Chantilly, VA).
Radiation Sensitization of Cells. Exponentially grow-
ing cells (2 3 105) were transferred to 60-mm culture dishes and
cultured for 24 h. After being washed twice with serum-free
medium, the cells were incubated with a mixture containing 15
mg of cationic liposome (Life Technologies) and various doses
of the anti-sense Prx II expression vector (pPrxII/AS) or anti-
sense/sense oligomers (AS1, 59-CGCGCGTTACCGGAGGC-
CAT-39; AS2, 59-ACGCCGTAATCCTCAGACAA-39; S1, 59-
ATGGCCTCCGGTAACGCGCG-39) in 1 ml of serum-free
medium for 4–6 h. The cells were washed with serum-free
medium, added to culture medium, and then cultured for 16 h.
Transfection was repeated one more time. At 16 h after trans-
fection, the cells were irradiated to g-rays with a 137Cs g-ray
source. After 14 days of incubation at 37°C, colonies larger than
200 mm in diameter were counted with a colony counter.
Determination of Apoptotic Cell Death. For DAPI
staining, 11A cells were transfected with AS1 twice and irradi-
ated with 3 Gy. After 48 h, the cells were seeded into 100-mm
tissue culture dishes. After the scheduled experiments, cells
were harvested and fixed with 3.7% formaldehyde on glass
slides, which were precoated with 1 mg/ml poly-L-lysine (Sig-
ma), and stained with 1 mg/ml DAPI in PBS for 30 min. After
slides were washed with PBS and mounted, the apoptotic cells
were counted under a fluorescence microscope (Axioplan2;
Zeiss).
For 7-AAD staining, 7-AAD (Sigma) was diluted in PBS at
a concentration of 1 mg/ml as a stock solution. 11A cells were
treated with either oligomers or radiation and mixed with
7-AAD stock solution to give a final 7-AAD concentration of 10
mg/ml. The cells were incubated for 20 min at 4°C in the dark
and analyzed using flow cytometry (Cellquest software; Becton
Dickinson). Analysis was performed as described by Schmid et
al. (20) to select cells undergoing apoptotic death.
Statistical Analysis. Every assay was performed in trip-
licate and repeated at least three times. Statistical analysis was
performed using the Mann-Whitney U test. The statistical sig-
nificance of the difference between control and treatment groups
was evaluated using one-way ANOVA. The criterion for statis-
tical significance was taken as P , 0.05. Means, SE, and Ps
were calculated using GraphPad PRISM, version 2.00 for Win-
dows (GraphPad Software, San Diego, CA).
RESULTS
Increased Expression of Prx II in Head-and-Neck Can-
cer Cells after Radiation Treatment. Because Prx II was
induced under oxidative stress and its overexpression had been
shown to protect cells from oxidative stress (13, 14), we first
investigated whether Prx II expression was related to the chemo-
and/or radiation resistance in head-and-neck tumor tissues. To
examine expression of Prx II and to investigate the role of Prx
II in chemo- and radiation resistance, we obtained tumor tissues
from two groups of patients: a chemotherapy-/radiotherapy-
sensitive group and a chemotherapy-/radiation-resistant pa-
tients. For head-and-neck cancerous tumors, chemotherapeutic
treatments such as cisplatin and 5-FU are commonly used prior
to radiotherapy. Thus, patients were received 100 mg/m2
cisplatin along with an injection of buffered-saline solution
containing mannitol and then received 5-FU (1000 mg/m2),
followed by g-radiation of the surviving tumors after chemo-
therapy. The profiles of the patients are listed in Table 1. Fig. 1
shows the strong expression of the Prx II mRNA in tumor
tissues from all four patients whose tumors did not respond to
combined chemo-/radiotherapy, whereas expression was weak
or not induced in five of five patients whose tumors completely
or partially regressed after radiation or combined chemotherapy/
radiation treatments. These results suggest that increased ex-
pression of Prx II in head and neck tumors might protect the
cells from radiation treatments, thereby contributing to cellular
resistance to radiation treatments in cancers.
Radioprotective Effect of Prx II. To examine whether
expression of Prx II was increased after irradiation, we irradi-
ated 11A cells with 3 Gy of g-radiation. Prx II expression in
11A cells gradually increased until 24 h after 3 Gy irradiation
(Fig. 2).
Because overexpression of Prx II has been shown to protect
ECV304 cells from oxidative stress induced by treatment with
t-butylperoxide or methyl mercury (15), we transfected 11A
Fig. 3 Cell survival after irradiation in Prx II-overexpressing 11A
cells. A, clonogenic survival of stable transfectant cell lines treated with
radiation. Three stable transfectant cells were pooled and irradiated with
0.5, 1, 2, and 4 Gy, and cell survival was determined using a clonogenic
assay as described in “Materials and Methods.” Results shown are the
means 6 SE (bars) of three independent experiments. Statistical signif-
icance of the difference between 11A/neo and 11A/Prx II cells: 0.5 Gy,
P , 0.05; 1 Gy, P , 0.05. B, Prx II expression in Prx II-overexpressing
cells. Protein lysates were resolved by SDS-PAGE, and Prx II expres-
sion was analyzed by Western blotting. Lane 1, 11A/neo; Lane 2,
11A/Prx II. b-actin was run as a control.
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cells with the pcDNA vector or CMV promoter carrying the
open-reading frame of the Prx II cDNA to examine whether
enhanced expression of Prx II protected the cells from radiation.
Three colonies were pooled and referred to as 11A/PrxII. In-
creased expression of Prx II in the stable transfectants enhanced
cell survival by ;50% after a 2-Gy dose of radiation (Fig. 3A).
The expression profile of Prx II in the pooled transfectants was
detected by Western blot analysis (Fig. 3B). From these data, we
suggest that the induced Prx II protein could protect the cells
from radiation-induced cellular damage.
Prx II Antisense as a Radiosensitizer. Because intro-
duction of a Prx II antisense into 11A cells prevented induction
of Prx II (Fig. 4B), antisense oligomers of Prx II were trans-
fected into 11A cells as described in “Materials and Methods,”
and we examined whether down-regulation of Prx II sensitized
the cells to radiation in vitro. Fig. 4A showed that with increas-
ing dosages of a Prx II antisense (AS1) in 11A cells, the more
cell death was observed. Treatment of a second antisense (AS2)
targeting the other open-reading frame sequence of the Prx II
cDNA showed a result similar to that for AS1 treatment (data
not shown). Treatment of 11A cells with a Prx II sense oligomer
(S1) did not alter cell viability compared with the control cells.
These results demonstrated that a Prx II antisense caused cell
death, which was dependent on the concentration of a Prx II
antisense used.
Although ;37% of 11A cells survived after 2 Gy of
irradiation, and ;90% survived after treatment with 0.1 mM Prx
II antisense (AS1), cell survival decreased to ;13% after 2 Gy
of irradiation in the presence of 0.1 mM Prx II antisense and to
;8% with irradiation in the presence of 1.0 mM Prx II antisense
(Fig. 4A). At 1.0 mM, Prx II antisense itself caused cell death in
;48% of 11A cells.
To confirm whether down-regulation of Prx II enhanced
cell death after irradiation, 11A cells were transiently trans-
fected with the antisense Prx II expression vector containing
the full-length antisense Prx II cDNA at three different con-
centrations. When the cells were irradiated with 2 Gy of
g-radiation in the presence of 0.1 mg/ml pcDNA3, it in-
creased cell death by ;53% compared with no g-radiation.
However, 0.1 mg/ml pPrxII/AS with 2 Gy of g-radiation
increased cell death by ;89% (Fig. 5). Thus, transfected cells
with a Prx II antisense showed a synergistic increase of cell
death after radiation compared with parent cells transfected
with pcDNA3. It is apparent from these data that expression
of Prx II can protect cells from radiation-induced cell death
and, therefore, that radiation sensitivity can be increased by
the inhibition of Prx II expression.
Prx II Antisense-induced Apoptosis. To demonstrate
that the presence of a Prx II antisense could stimulate apop-
tosis and enhance cellular damage after radiation, apoptotic
cell death was examined by flow cytometry using uptake of
the dye 7-AAD after treatment of 11A cells with a Prx II
antisense. Fig. 6A shows that Prx II antisense alone could
induce apoptosis. Furthermore, increased apoptotic cell death
was observed in the irradiated 11A cells pretreated with a Prx
II antisense. We also examined apoptotic cell death by DAPI
staining. The irradiated cells pretreated with Prx II antisense
demonstrated chromosome condensation, which was indica-
tive of apoptosis (Fig. 6B).
DISCUSSION
Although DNA-damaging agents such as g-radiation and
chemotherapeutic drugs have been widely used for the treatment
of numerous cancers, cells increasingly become resistant to
consecutive administration of chemotherapeutic drugs and radi-
Fig. 4 Cell survival in Prx II antisense oli-
gomer-treated 11A cells. A, 11A cells were
transfected with AS1 and S1 twice. The cells
were transfected with two different concen-
trations of AS1, 0.1 or 1.0 mM, before irra-
diation. After 2 Gy of irradiation, cell sur-
vival was measured by a clonogenic assay.
Column C, cells transfected with no DNA;
columns AS1 (0.1 mM) and AS1 (1.0 mM),
cells transfected with AS1; column 2 Gy,
cells irradiated with 2 Gy; columns AS1 (0.1
mM) 1 2 Gy and AS1 (1.0 mM) 1 2 Gy, cells
transfected with AS1 and then irradiated;
column S1, cells transfected with S1. Results
shown are the means 6 SE (bars) of three
independent experiments. Statistical signifi-
cance of the difference between control and
AS1 oligomer-transfected cells: AS1 (0.1
mM) 1 2 Gy, P , 0.001; AS1 (1.0 mM) 1 2
Gy, P , 0.001. B, inhibition of Prx II ex-
pression in Prx II antisense oligomer (AS1)-
transfected 11A cells. Expression of Prx II
was detected by Western blotting after trans-
fection with AS1. Lane C, cells transfected
with no DNA; Lane AS1, cells transfected
with AS1. b-actin was run as a control.
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ation. Therefore, studies involving strategies to overcome this
resistance to chemotherapy and radiation or to increase cellular
sensitivity to chemo- and radiation therapy contribute a critical
step for better cancer treatments. In this study, we showed
enhanced expression of Prx II in head-and-neck cancer cells that
are chemotherapy- and/or radiation-resistant and showed the
possible use of Prx II antisense as a radiosensitizer. Induction of
the ROS-activated proteins could protect cells from oxidative
cytolysis and reduce cellular damage by regulating cellular
redox status (21–24). Baker et al. (25) observed that the redox
protein thioredoxin was overexpressed in human primary lung
and colon tumors and that it prevented apoptosis through the
antioxidant mechanism. We also observed strong expression of
Prx II in tumor tissues isolated from patients with chemothera-
py- and/or radiation therapy-resistant tumors, whereas expres-
sion of Prx II was weak in the chemotherapy-/radiation-sensitive
tumor tissues, which regressed after radiotherapy (Fig. 1). Sim-
ilar to increased expression of Prx II in irradiated 11A cells, the
expression of Prx II in 11A cells was also enhanced by chemo-
therapeutic drugs such as cisplatin (5 mg/ml) and 5-FU (2.5
mg/ml; data not shown). It is therefore likely that intracellular
ROS induced by cisplatin, 5-FU, and radiation increase expres-
sion of Prx II in cancer cells, thereby endowing the cancer cells
with resistance. It should be noted here that overexpression of
Prx II has been observed to give more resistance to the chemo-
therapeutic drug CT-2584 in ECV304 cells (12), and we also
observed strong expression of Prx II in cisplatin-resistant stom-
ach cells compared with parent cells.6 From the above consid-
erations, we propose that Prx II functions not only as an anti-
oxidant protein but also as a stress-activated protein.
Prx II protein has been proposed to play a role as a
thiol-specific antioxidative protein (15) that reacts with thiol-
containing proteins such as thioredoxin. Because cellular thiol-
specific proteins are considered to regulate the activity of other
cellular proteins with thiols at regulatory domains (21, 24),
inhibition of Prx II activity could possibly affect signaling
pathway for cell growth and survival. Disruption of cellular
redox status has been shown to activate the caspase 3 cascade,
resulting in apoptosis (22). Zhang et al. (8) showed that over-
6 S-H. Park, Y. M. Chung, and D. Y. Young, unpublished data.
Fig. 5 Radiation sensitization of 11A cells after transfection with an
antisense Prx II expression plasmid (pPrxII/AS). 11A cells were trans-
fected with 0.025 (f), 0.05 (), and 0.1 mg/ml () pPrxII/AS, as
described in “Materials and Methods.” The cells were then irradiated
with 0.5, 1, 2, and 4 Gy. Cell survival was measured by a clonogenic
assay. As a control, the cells were transfected with 0.05 mg/ml of sense
Prx II expression plasmid (pPrxII/S; F). Results shown are the means 6
SE (bars) of three independent experiments. Statistical significance of
the difference between control (pcDNA3; E) and pPrxII/AS (0.1 mg/ml;
)-transfected cells: 0.5 Gy, P , 0.004; 1, 2, and 4 Gy, P , 0.001.
Fig. 6 Apoptosis induced by Prx II antisense. A, 11A cells were treated
with S1, AS1, or 3 Gy of radiation, then stained with 7-AAD. S1, cells
transfected with 1 mM S1; AS1, cells transfected with 1 mM AS1; 3 Gy,
cells irradiated with 3 Gy; AS113 Gy, cells irradiated with 3 Gy after
transfection with 1 mM AS1; a, apoptotic cells; d, dead cells. FCS-H,
forward scatter-height. B, 11A cells were transfected with AS1, irradi-
ated with 3 Gy, and then stained with DAPI.
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expression of Prx II inhibited apoptosis in Molt-4 leukemia cells
and functioned similarly to Bcl-2. One difference in function
between Prx II and Bcl-2 is that Prx II can prevent accumulation
of H2O2 in cells, thereby protecting cells from H2O2-induced
cell death. These observations could explain how treatment of
11A cells with a Prx II antisense induces apoptotic cell death.
Inhibition of Prx II expression did not influence the intracellular
concentration of GSH, an indicator of cellular redox status, in
irradiated 11A cells treated with a Prx II antisense (data not
shown). This observation was consistent with a previous result
that activity of Prx II was not regulated by intracellular concen-
trations of GSH (13). Therefore, blocking the expression of Prx
II might disrupt total cellular redox homeostasis but not the
GSH concentration, resulting in apoptosis (24). It should again
be emphasized that because overcoming radiation resistance is
critical for better cancer treatment, inactivation of the stress-
activated protein Prx II may be a promising approach to in-
creased radiation sensitivity in head-and-neck cancer cells.
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